Cargando…

F121. DOES RELAPSE CONTRIBUTE TO TREATMENT RESISTANCE? ANTIPSYCHOTIC RESPONSE IN FIRST- VS. SECOND-EPISODE SCHIZOPHRENIA

BACKGROUND: The objective of this study was to compare trajectories of antipsychotic response before and after relapse following response from a first episode of schizophrenia or schizoaffective disorder. METHODS: The current analysis included patients with a diagnosis of first-episode schizophrenia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeuchi, Hiroyoshi, Siu, Cynthia, Remington, Gary, Fervaha, Gagan, Foussias, George, Zipursky, Robert, Agid, Ofer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888338/ http://dx.doi.org/10.1093/schbul/sby017.652

Ejemplares similares

Treating Negative Symptoms in Schizophrenia: an Update
por: Remington, Gary, et al.
Publicado: (2016)

S76. A BEHAVIOURAL ECONOMIC ANALYSIS OF EFFORT-RELATED CHOICE IN SCHIZOPHRENIA
por: Fervaha, Gagan, et al.
Publicado: (2018)

F225. LEVODOPA AUGMENTATION OF ANTIPSYCHOTICS FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
por: Foussias, George, et al.
Publicado: (2018)

F219. NOVEL OBJECTIVE ASSESSMENT OF ACTIVITY ENGAGEMENT IN SCHIZOPHRENIA USING WIRELESS MOTION CAPTURE
por: Siddiqui, Ishraq, et al.
Publicado: (2018)

T121. RATES AND PREDICTORS OF RELAPSE FOLLOWING DISCONTINUATION OF ANTIPSYCHOTIC MEDICATION AFTER A FIRST EPISODE OF PSYCHOSIS
por: Bowtell, Meghan, et al.
Publicado: (2018)

S229. CAN LONG-ACTING INJECTABLE PALIPERIDONE DOSING BE OPTIMIZED WITH PLASMA LEVEL MEASUREMENTS?
por: Zipursky, Robert, et al.
Publicado: (2018)

Insight and subjective measures of quality of life in chronic schizophrenia
por: Siu, Cynthia O., et al.
Publicado: (2015)

Cognitive discrepancies, motivation and subjective well-being in people with schizophrenia
por: Krzyzanowski, Daniel, et al.
Publicado: (2021)

Interpreting a Multivariate Analysis of Functional Neuroimaging Data
por: Fervaha, Gagan, et al.
Publicado: (2012)

Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia
por: Washida, Kenji, et al.
Publicado: (2013)

The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
por: Tandon, Rajiv, et al.
Publicado: (2020)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Correction to: The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
por: Tandon, Rajiv, et al.
Publicado: (2020)

The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research
por: Potkin, Steven G., et al.
Publicado: (2020)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

S236. IS MAINTENANCE TREATMENT NEEDED WHEN THE FIRST EPISODE OF PSYCHOSIS IS NOT DUE TO SCHIZOPHRENIA?
por: Odejayi, Gbolahan, et al.
Publicado: (2018)

Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
por: Přikryl, Radovan, et al.
Publicado: (2012)

Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
por: García-Ruiz, Antonio J, et al.
Publicado: (2012)

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
por: Kim, Borah, et al.
Publicado: (2012)

Alterations of Intrinsic Connectivity Networks in Antipsychotic-Naïve First-Episode Schizophrenia
por: Anhøj, Simon, et al.
Publicado: (2018)

Second-Generation Antipsychotic Discontinuation in First Episode Psychosis: An Updated Review
por: Miller, Brian J., et al.
Publicado: (2011)

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration
por: Shi, Lizheng, et al.
Publicado: (2009)

Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients
por: Misiak, Błażej, et al.
Publicado: (2014)

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
por: Kumra, Sanjiv, et al.
Publicado: (2008)

Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia
por: Warikoo, Nisha, et al.
Publicado: (2014)

Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
por: McDonagh, Marian S., et al.
Publicado: (2020)

Atypical antipsychotics usage in long-term follow-up of first episode schizophrenia
por: Shrivastava, Amresh, et al.
Publicado: (2012)

Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year Comparison
por: Roh, Daeyoung, et al.
Publicado: (2015)

Gender Differences in the First-Year Antipsychotic Treatment for Chinese First-Episode Schizophrenia
por: Pu, Chengcheng, et al.
Publicado: (2020)

Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia
por: Morken, Gunnar, et al.
Publicado: (2008)

Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
por: Pilon, Dominic, et al.
Publicado: (2021)

Volume alteration of hippocampal subfields in first-episode antipsychotic-naïve schizophrenia patients before and after acute antipsychotic treatment
por: Li, Wenbin, et al.
Publicado: (2018)

Epigenetic clocks in relapse after a first episode of schizophrenia
por: Segura, Àlex-González, et al.
Publicado: (2022)

T121. BLUNTED AFFECT EARLY PROGRESSION IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA PATIENTS: 10-WEEK FOLLOW UP
por: Kagan, Simão, et al.
Publicado: (2020)

Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics?
por: Płaza, Olga, et al.
Publicado: (2022)

Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims
por: Stephenson, J J, et al.
Publicado: (2012)

The effect of second-generation antipsychotics on hippocampal volume in first episode of psychosis: longitudinal study
por: Bodnar, Michael, et al.
Publicado: (2016)

The effect of atypical antipsychotics on brain N-acetylaspartate levels in antipsychotic-naïve first-episode patients with schizophrenia: a preliminary study
por: Grošić, Vladimir, et al.
Publicado: (2014)

First-generation vs second-generation antipsychotic drugs: The ongoing saga
por: Gupta, Sumeet
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_0v3rh5d86ocee7jbjs24733vcl